21 clinical trials found.
-
A PHASE 1B/2A MULTICENTER OPEN-LABEL DOSEESCALATION STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF CC-220 MONOTHERAPY AND IN COMBINATION WITH OTHER TREATMENTS IN SUBJECTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA
The purpose of this study is to test the safety and to define the appropriate dose of an investigational drug (CC-220) and an investigational combination ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
A Phase 1 Open-label Multicenter Study to Evaluate the Safety of bb2121 in Subjects with High Risk Newly Diagnosed Multiple Myelorna (NDMM) (KarMMa-4)
The purpose of the study is to determine the safety of bb2121 in patients with high risk, newly diagnosed Multiple Myelorna (NDMM). bb2121 is a ...Phase
Interventional
TRIAL ROLE: Principal Investigator
-
Randomized Controlled Pivotal Trial of Autologous Bone Marrow Mononuclear Cells Using the CardiAMP Cell Therapy system in Patients with Post Myocardial Infarction Heart Failure (CardiAMP Heart Failure Trial)
The purpose of this study is to evaluate the CardiAMP cell therapy system as a treatment for patients with heart failure as a result of ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination with Nivolumab in Patients with Relapsed or Refractory Aggressive B-cell Lymphomas
The purpose of this study is to compare the anti-lymphoma activity and possible side effects of using CDX-1127 (varlilumab) along with another immunotherapy drug, nivolumab ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL RANDOMIZED MULTICENTER PHASE Ib/II TRIAL EVALUATING THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF MOSUNETUZUMAB (BTCT4465A) IN COMBINATION WITH POLATUZUMAB VEDOTIN IN PATIENTS WITH B-CELL NON-HODGKIN LYMPHOMA
The purpose of this study is to test the safety of mosunetuzumab at different dose levels when given in combination with polatuzumab vedotin and to ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
CDA Diefenbach Medpace Protocol ID ME-522-001 titled: A Phase 1 Open-label Study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies After Failure of Prior Standard Therapies
If you have been diagnosed with a B cell type cancer that has relapsed (come back) or is refractory (did not respond to previous treatment ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase I/II Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma
If you have been diagnosed with mantle cell lymphoma that has relapsed or refractory (lymphoma that has either come back or progressed on treatment), you ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase Ib/IIa Study Evaluating the Safety and Tolerability of Vitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations
If you have been diagnosed with intermediate or high risk Myelodysplastic Syndrome with a mutation in the Tet methylcytosine dioxygenase (abbreviated as TET) gene, you ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
AN OPEN-LABEL MULTICENTER PHASE l/1B TRIAL EVALUATING THE SAFETY ANDPHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT ANDCOMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORYB-CELL NON-HODGKIN S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA
If you have been diagnosed with non-Hodgkin s lymphoma (NHL) or chronic lymphocytic leukemia (CLL) that relapsed after previous treatment(s), did not respond to ...Phase
Interventional
TRIAL ROLE: Sub Investigator
-
A Phase 1 Study with an Expansion Cohort/Randomized Phase II Study of the Combination of Ipilimumab Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma
If you have been newly diagnosed with relapsed/refractory Hodgkin lymphoma and are exploring treatment options, you may qualify for a clinical trial studying effect ...
Phase
Interventional
TRIAL ROLE: Sub Investigator
